Carmed Pharmaceuticals Moves Forward in Entering the U.S. with Science-Driven Botanical Formulations

(SeaPRwire) –   BOCA RATON, FL – 21/03/2026 – (SeaPRwire) – Carmed Pharmaceuticals, a research-focused firm specializing in standardized botanical formulations, has launched its U.S. expansion, representing a new chapter in its global growth strategy. This step underscores the company’s ongoing commitment to incorporating scientifically validated methods into creating plant-based wellness products.

Established in 2019 by Mustafa Can, Carmed Pharmaceuticals grew out of extensive independent research into botanical bioactives, with special attention to carvacrol and its application in mechanism-driven formulation development. The company has since developed into an organized enterprise committed to connecting traditional botanical wisdom with contemporary pharmaceutical practices.

Carmed’s development approach focuses on producing standardized, reproducible formulations backed by analytical verification. Its product design strategy aims to enhance immune resilience, cellular performance, and overall physiological equilibrium through precisely crafted blends of bioactive compounds.

Founder’s Background and Scientific Direction

Mustafa Can, Carmed Pharmaceuticals’ founder, moved into botanical research after a maritime career as a ship captain. His pivot toward preventive wellness and longevity studies prompted an intensive phase of independent scientific investigation, encompassing comprehensive academic literature review and examination of phytochemical interactions.

Gradually, this autonomous research evolved into a concentrated initiative to comprehend and standardize bioactive botanical substances. Presently, Carmed functions with a committed team of roughly 25 specialists and partners with an extended network of medical professionals, laboratories, and research organizations to facilitate formulation advancement and scientific assessment.

Per company announcements, Carmed’s long-range plan emphasizes reinvesting in R&D, with particular emphasis on progressing formulation science and upholding stringent quality benchmarks.

“Our methodology is rooted in scientific rigor, prioritizing standardization and reproducibility,” Can stated. “Every formulation is crafted according to a distinct, quantifiable scientific framework.”

Research Framework and Manufacturing Standards

Carmed Pharmaceuticals utilizes a research-centered framework encompassing in vitro investigations, mechanism-focused assessments, and organized quality management protocols. All items are produced in GMP-compliant facilities that meet relevant regulatory guidelines.

Product Portfolio for the U.S. Market

In conjunction with its U.S. market debut, the firm intends to launch several principal formulations:

• Vacrol® Kids Spray – A carvacrol-infused spray designed to promote upper respiratory health and microbial equilibrium for children aged 4–11.
• S-Mix® – A multi-ingredient formulation engineered to bolster immune performance and healthy cellular function.
• Vacrol® Capsule – A standardized carvacrol-derived supplement intended to maintain microbial harmony and immune robustness.
• Vacrol-M® Capsule – A botanical combination developed to enhance respiratory health and immune system operation.
• Omevaq-3® – A specialized formulation created to promote cellular energy production and cognitive wellness.

Certain products, such as Vacrol® Kids Spray and S-Mix®, feature gluten-free, non-GMO, sugar-free, preservative-free, and halal-certified attributes.

The firm characterizes its formulation methodology as “rational synergy,” denoting the purposeful integration of multiple bioactive components engineered to engage various biological pathways uniformly and reproducibly.

Scientific Collaboration and Future Outlook

Carmed’s research programs receive backing via partnerships with academic entities and scientific labs. In January 2026, a peer-reviewed article in the journal Plants investigated the firm’s Vacrol® and S-Mix® formulations using preclinical lab and in ovo models, advancing ongoing studies on carvacrol-derived substances and complex botanical formulations.

The company stresses that these investigations constitute part of wider scientific inquiry and are not meant to substantiate claims concerning disease diagnosis, treatment, cure, or prevention.

As Carmed Pharmaceuticals penetrates the U.S. marketplace, its strategic priorities encompass regulatory adherence, scientific legitimacy, and sustained establishment within the preventive wellness domain. Further particulars concerning distribution and retail access will be disclosed in upcoming months.

About Carmed Pharmaceuticals

Carmed Pharmaceuticals is a scientifically-driven enterprise focusing on standardized botanical formulations founded on mechanism-driven design concepts. Leveraging Anatolia’s botanical legacy, the firm merges traditional botanical expertise with contemporary pharmaceutical techniques to create reproducible, quality-assured products.

Founded in 2019 after extensive preliminary research, Carmed functions with approximately 15 years of collective sector expertise. Its production operations comply with GMP standards, emphasizing safety, ecological accountability, and ongoing quality enhancement.

The firm creates formulations targeted at promoting preventive health, immune fortitude, and cellular well-being via scientifically-grounded approaches.